Phase II study of weekly docetaxel in patients with metastatic breast cancer

Background: This study was conducted to investigate die efficacy and toxicity of weekly docetaxel administration in patients with metastatic breast cancer. Patients and methods: Thirty-seven women were treated with 1 h infusions of docetaxel at 40 mg/m(2)/week after pre-medication with 8 mg dexamethazone. Each cycle consisted of three consecutive weekly treatments followed by a 1 week rest. All patients were assessed for toxicity; five patients were not assessable for clinical response, time to progression (TTP) and overall survival (CS) because of early treatment failure, but they were included in intention-to-treat analysis. Results: Patients received a median of four cycles (range, 1-9), with a median dose intensity of 28 mg/m(2)/week (range 22-30) and a median relative dose intensity of 0.95 (range 0.73-1.0). No patients showed complete response, whereas 14 had partial response, which accounted for 38% of objective response rate [95% confidence interval (CI) 22% to 53%]. In addition, three patients (8%, 95% CI 0% to 17%) had stable disease over 6 months, Clinical responses were achieved at a median of three cycles (range 1-4 cycles). The median TTP and OS were 5 and 12 months, respectively. The weekly docetaxel regimen was generally well tolerated. About half of the patients experienced grade a 1 neutropenia; only 19% had grade 3/4 neutropenia, including one case of grade 4. No febrile neutropenia was observed and fluid retention syndrome was uncommon. Non-hematologic toxicity, however, such as asthenia/fatigue, nail damage, tearing or hearing disorders, was seen with successive treatment cycles. Conclusions: Weekly docetaxel at 40 mg/m(2)/week is an active and feasible regimen for patients with metastatic breast cancer.